TFSA Investors: 1 Low-Risk Value Stock With Significant Upside

Knight Therapeutics Inc. (TSX:GUD) is focused on building a portfolio of innovative products through in-licensing or acquiring product rights.

| More on:
Hand arranging wood block stacking as step stair with arrow up.

Image source: Getty Images

Knight Therapeutics (TSX:GUD) was founded in 2014, and the company aspires to become a leading, global specialty pharmaceutical company. Knight is focused on building a portfolio of innovative products through in-licensing or acquiring product rights.

Transformative acquisition

In 2019, the company announced that it had entered an agreement to acquire the controlling interest in Grupo Biotscana (GBT), a pan-Latin American specialty pharmaceutical company. GBT operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as oncology and hematology, infectious diseases, and other specialty therapeutic areas. GBT is currently present throughout 10 Latin American countries where it operates through four companies.

In 2019, Knight completed the acquisition of 51.2% of GBT. The company later announced that it had requested authorization to carry out a unified tender offer to acquire the balance of GBT. Upon settlement of the united tender offer, Knight acquired 99.9% ownership in GBT.

Significant buybacks

Since inception, the company has raised gross proceeds of $685 million through issuance of 109 million common shares at prices ranging from $3.50 to $10. In 2019, Knight launched a normal course issuer bid (NCIB) to acquire up to 12 million common shares of the company. In 2020, Knight completed the NCIB and purchased cumulative total of 12 million common shares at an average price of $7.14 per share. Subsequently, Knight launched a second NCIB to acquire up to 10.8 million common shares of the company.

In the most recent quarter, the company has acquired 3.8 million common shares at an average price of just $5.40 per share under the second NCIB. Further, in December 2020, the company filed a shelf prospectus, which enables Knight to offer for sale up to $360 million of common shares, subscription receipts, and debt securities of Knight during the 25-month period after filing of the shelf. This provides the company with the financial ability to make strategic acquisitions if needed.

Flexible business model

Knight has committed to invest over $125 million with nine life sciences debt or equity fund managers, all of which can leverage life sciences industry experience and existing relationships with key life science companies to help secure product rights for Knight. During 2019, Knight determined that while the fund strategy has been financially successful, the strategy has not been successful from a business development perspective as it has led to only two product licence agreements. Consequently, Knight demonstrated flexibility by determining that it would not be investing in any new venture capital funds.

Knight has invested over $170 million through strategic debt financing to over a dozen companies with the objective of deploying capital in low-risk, fair-return opportunities while helping to secure Canadian and select international product rights. During 2020, Knight continued building the company’s infrastructure to acquire in-licence and commercialize innovative products for the Canadian and Latin American market. In 2020, the company continued to advance Knight’s Canadian portfolio by obtaining approvals from Health Canada for several products.

At current prices, Knight appears to be ridiculously cheap. The company is taking advantage of market inefficiencies by buying back a lot of stock. This should increase intrinsic value and serve long-term shareholders well.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar owns shares of KNIGHT THERAPEUTICS INC.

More on Investing

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »

edit Woman in skates works on laptop
Dividend Stocks

3 No-Brainer Stocks to Buy Under $30

These three stocks all offer a huge deal for investors looking for dividends, as well as growth that will last.

Read more »

Business man on stock market financial trade indicator background.
Tech Stocks

1 Growth Stock Down 50 Percent to Buy Right Now

There are plenty of growth stocks in the market worth considering, but Shopify (TSX:SHOP) looks like one of the best…

Read more »